David Shulkin Net Worth

David Shulkin biography

David J. Shulkin M.D. serves as Independent Director of the Company. He currently serves as President and Chief Executive Officer of Shulkin Solutions, Inc., a company dedicated to promoting innovation in healthcare and advocating for veterans and underserved populations. Prior to his current position, Dr. Shulkin served in various capacities at the U.S. Department of Veterans Affairs (the "VA") under two U.S. presidential Administrations, including as Secretary from 2017 to 2018 and as Under Secretary for Health from 2015 to 2017. Prior to his work at the VA, Dr. Shulkin served as chief executive of leading hospitals and health systems including Beth Israel in New York City and Morristown Medical center in Northern New Jersey. Dr. Shulkin received a B.A. from Hampshire College and an M.D. from the Medical College of Pennsylvania. In addition, Dr. Shulkin completed residencies in internal medicine at Yale University School of Medicine and the University of Pittsburgh School of Medicine, was a fellow in General Medicine at the University of Pittsburgh School of Medicine and was a Robert Wood Johnson Foundation Clinical Scholar at the University of Pennsylvania School of Medicine. He is also certified by the American Board of Internal Medicine.

How old is David Shulkin?

David Shulkin is 60, he's been the Independent Director of Orasure Technologies since 2020. There are 4 older and 13 younger executives at Orasure Technologies. The oldest executive at Orasure Technologies Inc. is Ronny Lancaster, 68, who is the Independent Director.

What's David Shulkin's mailing address?

David's mailing address filed with the SEC is 220 EAST FIRST STREET, , BETHLEHEM, PA, 18015.

Insiders trading at Orasure Technologies

Over the last 21 years, insiders at Orasure Technologies have traded over $21,897,384 worth of Orasure Technologies stock and bought 196,200 units worth $1,037,188 . The most active insiders traders include Douglas A Michels, Ronald H Spair, and Michael J Gausling. On average, Orasure Technologies executives and independent directors trade stock every 43 days with the average trade being worth of $221,123. The most recent stock trade was executed by Kathleen Gallagher Weber on 19 December 2023, trading 24,129 units of OSUR stock currently worth $194,238.

What does Orasure Technologies do?

based in bethlehem, pennsylvania, orasure technologies is a leader in the development, manufacture and distribution of oral fluid diagnostic and collection devices and other technologies designed to detect or diagnose critical medical conditions. these products include tests for the detection of antibodies to the hiv virus, including the oraquick® in-home hiv test, oraquick advance® rapid hiv-1/2 antibody test and the orasure® hiv-1 oral specimen collection device, a test for antibodies to the hcv virus, the oraquick® hcv rapid antibody test, and oral fluid testing solutions for drugs of abuse testing, including intercept® oral fluid drug testing system and q.e.d.® saliva alcohol test. orasure also manufactures and sells several leading cryosurgical products. these include: histofreezer®, a product for the cryosurgical removal of common and plantar warts and several other benign skin lesions, sold to the professional or physician office market, as well as an over-the-counter product fo

Orasure Technologies executives and stock owners

Orasure Technologies executives and other stock owners filed with the SEC include:

• Stephen Tang,
  President, Chief Executive Officer, Director
• Dr. Stephen S. Tang,
  Pres, CEO & Director
• Roberto Cuca,
  Chief Financial Officer
• Kathleen Gallagher Weber,
  Exec. VP & Bus. Unit Leader of Molecular Solutions
• Jack Jerrett,
  Senior Vice President, Chief Compliance Officer, General Counsel, Secretary
• Kathleen Weber,
  Executive Vice President, Business Unit Leader, Molecular Solutions at DNAG
• Scott Gleason,
  Sr. VP of Investor Relations & Corp. Communications and Interim CFO
• Michael Celano,
  Independent Chairman of the Board
• Ronny Lancaster,
  Independent Director
• Eamonn Hobbs,
  Independent Director
• Mara Aspinall,
  Independent Director
• James Datin,
  Independent Director
• David Shulkin,
  Independent Director
• Lelio Marmora,
  Director
• Michele Miller,
  Vice President - Finance, Controller, Assistant Secretary
• Lisa Nibauer,
  Executive Vice President, Business Unit Leader, Infectious Disease
• Amy Steigerwalt,
  VP of HR
• David A. Rappaport C.F.A., CFA,
  Sr. VP Corp. Devel., Strategy & Integration
• Carrie Eglinton Manner,
  Pres, CEO & Director
• Michele Marie Miller,
  VP of Fin., Controller & Assistant Sec.
• Agnieszka M. Gallagher J.D.,
  Gen. Counsel, Chief Compliance Officer & Sec.
• Lisa Nibauer,
  Pres of Diagnostics
• Jeanne Mell,
  VP of Corp. Communications
• Michele Marie Anthony,
  SVP Finance & CAO
• Douglas G Watson,
  Director
• Mark L Kuna,
  VP & Controller
• Roger L Pringle,
  Director
• Michael Reed,
  SVP R&D and CSO
• Ronald H Spair,
  Exec. VP & CFO
• Douglas A Michels,
  President and CEO
• Brian Smith,
  EVP & BU Lead - Molecular
• Nancy J Gagliano,
  Director
• Gregory B Lawless,
  Director
• Aradhana Sarin,
  Director
• Gerald M Ostrov,
  Director
• Eric Whitters,
  SVP, Research and Development
• Stephen R Lee,
  EVP & Chief Science Officer
• P Michael Formica,
  Exec. VP - Operations
• Michael J Gausling,
  President & CEO
• Joseph E Zack,
  Exec. VP, Marketing & Sales
• Manuel O. Mendez,
  VP, Marketing and Sales
• Frank G Hausmann,
  Director
• Jack Goldstein,
  Director
• Carter H Eckert,
  Director
• Ii Anthony Zezzo,
  EVP & BU Lead - Infectious
• Charles W Patrick,
  Director
• John P. Kenny,
  Director
• Robert W. Mc Mahon,
  Director
• Agnieszka Gallagher,
  General Counsel & CCO
• Scott Gleason,
  Interim CFO/SVP IR
• Anne Clem Whitaker,
  Director
• Manner Carrie Eglinton,
  President & CEO
• Kenneth J Mc Grath,
  Chief Financial Officer